JP Morgan Maintains Overweight on Syndax Pharmaceuticals, Maintains $34 Price Target
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Anupam Rama maintains an Overweight rating on Syndax Pharmaceuticals (NASDAQ:SNDX) with a $34 price target.
May 21, 2024 | 5:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JP Morgan analyst Anupam Rama has reiterated an Overweight rating on Syndax Pharmaceuticals (NASDAQ:SNDX) and maintained a $34 price target.
The reaffirmation of an Overweight rating and a $34 price target by a reputable analyst from JP Morgan is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100